Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
1.510
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.510
Bid (Size)
1.480 (75)
Ask (Size)
1.530 (70)
Prev. Close
1.510
Today's Range
1.510 - 1.510
52wk Range
1.120 - 9.080
Shares Outstanding
81,632,619
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
March 05, 2025
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
Via
Stocktwits
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
March 05, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Performance
YTD
+15.27%
+15.27%
1 Month
+25.83%
+25.83%
3 Month
-24.12%
-24.12%
6 Month
-60.05%
-60.05%
1 Year
-82.46%
-82.46%
More News
Read More
Peering Into Editas Medicine's Recent Short Interest
February 25, 2025
Via
Benzinga
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
February 24, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
12 Analysts Have This To Say About Editas Medicine
December 11, 2024
Via
Benzinga
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
October 23, 2024
Via
Benzinga
Earnings Scheduled For March 5, 2025
March 05, 2025
Via
Benzinga
What's going on in today's session
February 20, 2025
Via
Chartmill
Top movers in Thursday's session
February 20, 2025
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
February 20, 2025
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.
February 19, 2025
Via
Chartmill
Here are the top movers in Wednesday's session.
February 19, 2025
Via
Chartmill
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
January 13, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
December 17, 2024
Via
Benzinga
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
December 13, 2024
Via
Benzinga
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
December 13, 2024
Via
Benzinga
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
December 13, 2024
Via
Benzinga
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 12, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
November 30, 2024
Via
Talk Markets
Topics
Stocks / Equities
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
November 25, 2024
Via
Benzinga
Editas Medicine to Participate in Upcoming Investor Conferences
November 06, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.